Introduction: Morbid obesity is a chronic disease that reduces life expectancy and is a major risk factor for type II diabetes. Bariatric surgery is the only therapy that produces significant and sustained weight loss and has been reported to result in clinical and biochemical resolution of type II diabetes.
Aim: Measure the effect of gastric bypass surgery on Type II diabetes mellitus
Hypothesis: Gastric bypass improves fasting blood glucose, HbA1C and plasma insulin levels
Methods: This is a review of prospectively collected database of morbidly obese subjects undergoing laparoscopic Roux-en-Y gastric bypass (LRYGBP) between August 2001 and October 2006. Consecutive series of patients with type II diabetes and morbid obesity and meeting NIH criteria for bariatric surgery were chosen. Demographic data, weight and height were recorded. Fasting plasma glucose, HbA1C and fasting insulin levels were measured preoperatively and at 3 and 12 months postoperatively.
Results: 49 patients (female 43) had complete follow-up and data at 3 and 12 months. The mean age was 37 yrs (18-67yrs) with weight and BMI of Weight 298 lb (186-479 lb) and 48.3 kg/m2 (35-73) respectively. Mean percentage excess weight loss was 70% at 12 months. Fasting blood glucose (mg/dl) fell from a preoperative value 161 to 98 and 88 at 3 and 12 months respectively (p
Program Number: P065